Influence of camrelizumab on serum tumor markers and quality of life in patients with advanced cervical cancer
Objective:To explore the influence of camrelizumab on serum tumor markers and quality of life in patients with advanced cervical cancer.Methods:Eighty patients with advanced cervical cancer admitted to our hospital between February 2022 and February 2023 were divided into two groups the random number table method,with 40 patients in each group.The control group received concurrent chemoradiotherapy.Medical linear accelerator 6 MV X-ray conformal intensity-modulated radiotherapy was used.The irradiation dose was selected based on the patient's condition.The irradiation doses for different parts were different.For example,the positive pelvic and retroperitoneal lymph nodes received 60 Gy,and the outside of the pelvis received 45～50.4 Gy,5 times a week.Chemotherapy method:This was performed in the 1st,4th,and 7th weeks after the start of radiotherapy.A total of 21 days were used as a cycle,and three consecutive cycles were performed.Use of 30 mg/m2 cisplatin+135 mg/m2 paclitaxel.Paclitaxel was administered on the first day and cisplatin was used on the 2nd to 4th days.Based on this,the observation group was treated with 200 mg of camrelizumab.The drug was administered one day after cisplatin administration and once every 21 days thereafter.The short-term efficacy,tumor markers[squamous cell carcinoma-associated antigen(SCC-Ag),carbohydrate antigen 199(CA199),cytokeratin 19 fragment(CYFRA21H),carbohydrate antigen 125(CA125)],quality of life,and toxicity and side effects were compared between the two groups.Results:The disease control rate in the observation group was 85.00％(34/40),which was higher than that in the control group(60.00％,24/40).The difference was statistically significant(P＜0.05).There were no statistically significant differences in SCC-Ag,CA199,CYFRA21H,CA125,Functional Assessment of Cancer Therapy-General(FACT-G),or Cervical Cancer Subscale(CxCS)scores of cancer patients before treatment between the two groups(P＞0.05).After treatment,SCC-Ag,CA199,CYFRA21H,and CA125 levels in both groups decreased,and the FACT-G and CxCS scores increased.Changes in the observation group were more obvious.The difference was statistically significant(P＜0.05).There were no statistically significant differences in toxicity and side effects between the two groups(P＞0.05).Conclusion:Camrelizumab is effective for the treatment of patients with advanced cervical cancer.It can improve the disease control rate and quality of life of patients,reduce the level of tumor markers,and will not increase toxicity and side effects.Thus,it is safe and reliable for clinical application.
advanced cervical cancercamrelizumabserum tumor markersquality of life
万方数据
维普
